Skip to main content
. Author manuscript; available in PMC: 2012 Dec 9.
Published in final edited form as: Circ Res. 2011 Oct 27;109(12):1363–1374. doi: 10.1161/CIRCRESAHA.111.250282

Figure 7. Administration of r-Wnt3a following MI leads to impaired cardiac performance.

Figure 7

(A) Quantification of heart weight to body weight ratios in Sham (n=8), Vehicle (n=12) and r-Wnt3a injected animals (n=12). (B) Measurement of infarct size in Vehicle and r-Wnt3a injected hearts (n=8). Echocardiographic assessment of (C) intra-ventricular septal thickness in diastole (IVS;d), (D) left ventricular internal dimension in diastole (LVID;d), (E) fractional shortening and (F) fractional area change (Sham, n=7; Vehicle, n=9; r-Wnt3a, n=10). All measurements were performed at 1 week post-MI. Data are mean ± s.e.m. * P≤0.05 all samples to Sham, # P≤0.05 r-Wnt3a to Vehicle.